Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension
Patients with systolic heart failure (HF) who develop secondary pulmonary hypertension (PH) have reduced exercise capacity and increased mortality compared with HF patients without PH. We tested the hypothesis that sildenafil, an effective therapy for pulmonary arterial hypertension, would lower pul...
Saved in:
Published in | Circulation (New York, N.Y.) Vol. 116; no. 14; pp. 1555 - 1562 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
02.10.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Patients with systolic heart failure (HF) who develop secondary pulmonary hypertension (PH) have reduced exercise capacity and increased mortality compared with HF patients without PH. We tested the hypothesis that sildenafil, an effective therapy for pulmonary arterial hypertension, would lower pulmonary vascular resistance and improve exercise capacity in patients with HF complicated by PH.
Thirty-four patients with symptomatic HF and PH were randomized to 12 weeks of treatment with sildenafil (25 to 75 mg orally 3 times daily) or placebo. Patients underwent cardiopulmonary exercise testing before and after treatment. The change in peak VO2 from baseline, the primary end point, was greater in the sildenafil group (1.8+/-0.7 mL x kg(-1) x min(-1)) than in the placebo group (-0.27 mL x kg(-1) x min(-1); P=0.02). Sildenafil reduced pulmonary vascular resistance and increased cardiac output with exercise (P<0.05 versus placebo for both) without altering pulmonary capillary wedge or mean arterial pressure, heart rate, or systemic vascular resistance. The ability of sildenafil treatment to augment peak VO2 correlated directly with baseline resting pulmonary vascular resistance (r=0.74, P=0.002) and indirectly with baseline resting right ventricular ejection fraction (r=-0.64, P=0.01). Sildenafil treatment also was associated with improvement in 6-minute walk distance (29 m versus placebo; P=0.047) and Minnesota Living With Heart Failure score (-14 versus placebo; P=0.01). Subjects in the sildenafil group experienced fewer hospitalizations for HF and a higher incidence of headache than those in the placebo group without incurring excess serious adverse events.
Phosphodiesterase 5 inhibition with sildenafil improves exercise capacity and quality of life in patients with systolic HF with secondary PH. |
---|---|
AbstractList | Patients with systolic heart failure (HF) who develop secondary pulmonary hypertension (PH) have reduced exercise capacity and increased mortality compared with HF patients without PH. We tested the hypothesis that sildenafil, an effective therapy for pulmonary arterial hypertension, would lower pulmonary vascular resistance and improve exercise capacity in patients with HF complicated by PH.
Thirty-four patients with symptomatic HF and PH were randomized to 12 weeks of treatment with sildenafil (25 to 75 mg orally 3 times daily) or placebo. Patients underwent cardiopulmonary exercise testing before and after treatment. The change in peak VO2 from baseline, the primary end point, was greater in the sildenafil group (1.8+/-0.7 mL x kg(-1) x min(-1)) than in the placebo group (-0.27 mL x kg(-1) x min(-1); P=0.02). Sildenafil reduced pulmonary vascular resistance and increased cardiac output with exercise (P<0.05 versus placebo for both) without altering pulmonary capillary wedge or mean arterial pressure, heart rate, or systemic vascular resistance. The ability of sildenafil treatment to augment peak VO2 correlated directly with baseline resting pulmonary vascular resistance (r=0.74, P=0.002) and indirectly with baseline resting right ventricular ejection fraction (r=-0.64, P=0.01). Sildenafil treatment also was associated with improvement in 6-minute walk distance (29 m versus placebo; P=0.047) and Minnesota Living With Heart Failure score (-14 versus placebo; P=0.01). Subjects in the sildenafil group experienced fewer hospitalizations for HF and a higher incidence of headache than those in the placebo group without incurring excess serious adverse events.
Phosphodiesterase 5 inhibition with sildenafil improves exercise capacity and quality of life in patients with systolic HF with secondary PH. BACKGROUND: Patients with systolic heart failure (HF) who develop secondary pulmonary hypertension (PH) have reduced exercise capacity and increased mortality compared with HF patients without PH. We tested the hypothesis that sildenafil, an effective therapy for pulmonary arterial hypertension, would lower pulmonary vascular resistance and improve exercise capacity in patients with HF complicated by PH. METHOD:S: and Results- Thirty-four patients with symptomatic HF and PH were randomized to 12 weeks of treatment with sildenafil (25 to 75 mg orally 3 times daily) or placebo. Patients underwent cardiopulmonary exercise testing before and after treatment. The change in peak {Vdot}O sub(2) from baseline, the primary end point, was greater in the sildenafil group (1.8 plus or minus 0.7 mL . kg super(-1) . min super(-1)) than in the placebo group (-0.27 mL . kg super(-1) . min super(-1); P=0.02). Sildenafil reduced pulmonary vascular resistance and increased cardiac output with exercise (P<0.05 versus placebo for both) without altering pulmonary capillary wedge or mean arterial pressure, heart rate, or systemic vascular resistance. The ability of sildenafil treatment to augment peak {Vdot}O sub(2) correlated directly with baseline resting pulmonary vascular resistance (r=0.74, P=0.002) and indirectly with baseline resting right ventricular ejection fraction (r=-0.64, P=0.01). Sildenafil treatment also was associated with improvement in 6-minute walk distance (29 m versus placebo; P=0.047) and Minnesota Living With Heart Failure score (-14 versus placebo; P=0.01). Subjects in the sildenafil group experienced fewer hospitalizations for HF and a higher incidence of headache than those in the placebo group without incurring excess serious adverse events. CONCLUSIONS: Phosphodiesterase 5 inhibition with sildenafil improves exercise capacity and quality of life in patients with systolic HF with secondary PH. Background— Patients with systolic heart failure (HF) who develop secondary pulmonary hypertension (PH) have reduced exercise capacity and increased mortality compared with HF patients without PH. We tested the hypothesis that sildenafil, an effective therapy for pulmonary arterial hypertension, would lower pulmonary vascular resistance and improve exercise capacity in patients with HF complicated by PH. Methods and Results— Thirty-four patients with symptomatic HF and PH were randomized to 12 weeks of treatment with sildenafil (25 to 75 mg orally 3 times daily) or placebo. Patients underwent cardiopulmonary exercise testing before and after treatment. The change in peak V̇ o 2 from baseline, the primary end point, was greater in the sildenafil group (1.8±0.7 mL · kg −1 · min −1 ) than in the placebo group (−0.27 mL · kg −1 · min −1 ; P =0.02). Sildenafil reduced pulmonary vascular resistance and increased cardiac output with exercise ( P <0.05 versus placebo for both) without altering pulmonary capillary wedge or mean arterial pressure, heart rate, or systemic vascular resistance. The ability of sildenafil treatment to augment peak V̇ o 2 correlated directly with baseline resting pulmonary vascular resistance ( r =0.74, P =0.002) and indirectly with baseline resting right ventricular ejection fraction ( r =−0.64, P =0.01). Sildenafil treatment also was associated with improvement in 6-minute walk distance (29 m versus placebo; P =0.047) and Minnesota Living With Heart Failure score (−14 versus placebo; P =0.01). Subjects in the sildenafil group experienced fewer hospitalizations for HF and a higher incidence of headache than those in the placebo group without incurring excess serious adverse events. Conclusions— Phosphodiesterase 5 inhibition with sildenafil improves exercise capacity and quality of life in patients with systolic HF with secondary PH. |
Author | SHAHZAD, Khurram SYSTROM, David M CAMUSO, Janice M SHAH, Ravi HUNG, Judy TAWAKOL, Ahmed SEMIGRAN, Marc J BLOCH, Kenneth D PAPPAGIANOPOULOS, Paul P GERSZTEN, Robert E LEWIS, Gregory D |
Author_xml | – sequence: 1 givenname: Gregory D surname: LEWIS fullname: LEWIS, Gregory D organization: Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, United States – sequence: 2 givenname: Ravi surname: SHAH fullname: SHAH, Ravi organization: Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, United States – sequence: 3 givenname: Marc J surname: SEMIGRAN fullname: SEMIGRAN, Marc J organization: Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, United States – sequence: 4 givenname: Khurram surname: SHAHZAD fullname: SHAHZAD, Khurram organization: Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, United States – sequence: 5 givenname: Janice M surname: CAMUSO fullname: CAMUSO, Janice M organization: Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, United States – sequence: 6 givenname: Paul P surname: PAPPAGIANOPOULOS fullname: PAPPAGIANOPOULOS, Paul P organization: Pulmonary and Critical Care Unit Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, United States – sequence: 7 givenname: Judy surname: HUNG fullname: HUNG, Judy organization: Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, United States – sequence: 8 givenname: Ahmed surname: TAWAKOL fullname: TAWAKOL, Ahmed organization: Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, United States – sequence: 9 givenname: Robert E surname: GERSZTEN fullname: GERSZTEN, Robert E organization: Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, United States – sequence: 10 givenname: David M surname: SYSTROM fullname: SYSTROM, David M organization: Pulmonary and Critical Care Unit Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, United States – sequence: 11 givenname: Kenneth D surname: BLOCH fullname: BLOCH, Kenneth D organization: Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19141945$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17785618$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkdGO1CAUholZ486uvoLBC73rCG2B9nIyUXeSiZvo7nVzoIcMhtIutOq8gM8t40yy8YoDfP_h8P835CqMAQl5x9mac8k_bnffto_7zcPu_uvmbrPmTK0Vl5WqXpAVF2Vd1KJqr8iKMdYWqirLa3KT0o-8zZB4Ra65Uo2QvFmRP9-d7zGAdZ66YYrjT0wUf2M0LiE1MIFx85FC6OnTAv5Uj5Z6Z5G6QCeYHYY50V9uPtB0TPPonaEHhDhTC84vEf9pE5ox9BCPdFr8MIZTdThOGGcMyY3hNXlpwSd8c1lvyePnTw_bu2J__2W33ewLI0o5F1UjKsu1xLoWNUgDopVGaKMrMLUGW-sGeqlLzTVIrfINY0LoXpmTIwaqW_Lh3Df_9GnBNHeDSwa9h4DjkrqSVUwx1WSwPYMmjilFtN0U3ZDH7jjrTiF0_4eQj1V3DiFr314eWfSA_bPy4noG3l8ASAa8jRCy3c9cy2ve5on_Au-imAU |
CODEN | CIRCAZ |
CitedBy_id | crossref_primary_10_1345_aph_1Q421 crossref_primary_10_1016_j_jacc_2009_01_004 crossref_primary_10_4103_2045_8932_87303 crossref_primary_10_1016_j_hfc_2011_11_002 crossref_primary_10_1016_j_ijcard_2013_10_038 crossref_primary_10_1161_CIRCHEARTFAILURE_117_004255 crossref_primary_10_1007_s11897_016_0284_x crossref_primary_10_21693_1933_088X_9_2_92 crossref_primary_10_1016_j_jacc_2009_05_021 crossref_primary_10_1016_j_jacbts_2020_07_011 crossref_primary_10_3390_ijms23042145 crossref_primary_10_1161_CIRCULATIONAHA_109_887570 crossref_primary_10_1016_S1885_5857_10_70094_3 crossref_primary_10_3390_ijms18071436 crossref_primary_10_1007_s11897_018_0377_9 crossref_primary_10_1161_CIRCULATIONAHA_112_000667 crossref_primary_10_1002_ejhf_2527 crossref_primary_10_1097_HCO_0b013e3283501960 crossref_primary_10_1038_nrcardio_2010_144 crossref_primary_10_5339_gcsp_2014_42 crossref_primary_10_1007_BF03256167 crossref_primary_10_1164_rccm_201104_0662CI crossref_primary_10_1016_j_jacc_2010_05_046 crossref_primary_10_7759_cureus_33363 crossref_primary_10_1136_openhrt_2021_001808 crossref_primary_10_1016_j_jacc_2011_07_051 crossref_primary_10_1016_j_pcad_2016_06_003 crossref_primary_10_1007_s11897_010_0031_7 crossref_primary_10_1016_S1131_3587_09_71775_3 crossref_primary_10_1007_s11897_014_0222_8 crossref_primary_10_1016_j_jacc_2016_05_047 crossref_primary_10_1016_j_repc_2012_09_001 crossref_primary_10_1007_s11936_013_0249_2 crossref_primary_10_1161_CIR_0000000000000560 crossref_primary_10_1378_chest_14_0670 crossref_primary_10_1016_j_jacc_2011_10_900 crossref_primary_10_1007_s00421_011_2085_y crossref_primary_10_1016_j_pcad_2014_11_002 crossref_primary_10_1161_CIRCHEARTFAILURE_114_001825 crossref_primary_10_1016_j_ejcdt_2013_12_003 crossref_primary_10_1016_j_cjca_2011_09_018 crossref_primary_10_1161_CIRCHEARTFAILURE_108_830570 crossref_primary_10_1152_physrev_00015_2023 crossref_primary_10_1016_j_ijcard_2013_10_012 crossref_primary_10_1073_pnas_1800996115 crossref_primary_10_1016_j_vph_2023_107180 crossref_primary_10_1053_j_jvca_2011_02_022 crossref_primary_10_1007_s11936_016_0438_x crossref_primary_10_1161_CIRCHEARTFAILURE_111_963785 crossref_primary_10_1038_nrcardio_2017_224 crossref_primary_10_1055_a_2145_4792 crossref_primary_10_1093_eurjhf_hfp171 crossref_primary_10_1177_2040622319868376 crossref_primary_10_1371_journal_pone_0157171 crossref_primary_10_1161_CIRCHEARTFAILURE_111_962217 crossref_primary_10_1161_CIRCULATIONAHA_111_085761 crossref_primary_10_1007_s11897_008_0034_9 crossref_primary_10_1016_j_pharmthera_2009_02_009 crossref_primary_10_1007_s13239_017_0310_5 crossref_primary_10_1016_j_ccl_2012_03_011 crossref_primary_10_1111_j_1751_7133_2008_00026_x crossref_primary_10_1007_s12350_012_9613_y crossref_primary_10_1007_s10557_021_07275_y crossref_primary_10_1086_678471 crossref_primary_10_1111_j_2047_2927_2012_00048_x crossref_primary_10_1161_CIRCHEARTFAILURE_110_959437 crossref_primary_10_1161_CIRCHEARTFAILURE_114_001915 crossref_primary_10_12965_jer_1938712_356 crossref_primary_10_1016_j_acvd_2017_01_010 crossref_primary_10_1161_JAHA_112_003731 crossref_primary_10_1002_prca_200780079 crossref_primary_10_1007_s00296_012_2466_5 crossref_primary_10_1016_j_chest_2017_12_008 crossref_primary_10_3390_ph15081024 crossref_primary_10_3390_ijms24021069 crossref_primary_10_1016_j_bbrc_2013_06_002 crossref_primary_10_1007_s11897_011_0061_9 crossref_primary_10_1111_apha_12295 crossref_primary_10_1016_S0828_282X_09_70477_5 crossref_primary_10_1016_j_rmed_2017_08_006 crossref_primary_10_1053_j_jvca_2019_02_008 crossref_primary_10_1016_S1885_5857_10_70066_9 crossref_primary_10_1086_685548 crossref_primary_10_1007_s12181_010_0269_z crossref_primary_10_1161_JAHA_115_002477 crossref_primary_10_1038_nrcardio_2009_32 crossref_primary_10_1161_CIRCRESAHA_111_259242 crossref_primary_10_1186_1471_2261_10_9 crossref_primary_10_4137_CMC_S38447 crossref_primary_10_1016_j_hfc_2018_02_006 crossref_primary_10_1016_j_jacc_2008_11_051 crossref_primary_10_1161_CIRCHEARTFAILURE_112_000091 crossref_primary_10_1016_j_rmed_2016_11_010 crossref_primary_10_1016_j_trsl_2020_08_006 crossref_primary_10_1016_j_healun_2015_10_019 crossref_primary_10_1161_CIRCULATIONAHA_109_192230 crossref_primary_10_1007_s00740_016_0146_x crossref_primary_10_1016_j_ijcard_2011_05_046 crossref_primary_10_1111_j_1751_7176_2012_00669_x crossref_primary_10_1038_hr_2009_113 crossref_primary_10_1586_ecp_10_15 crossref_primary_10_1517_14740338_2012_714770 crossref_primary_10_1016_j_lfs_2018_12_056 crossref_primary_10_1155_2011_381787 crossref_primary_10_1093_eurheartj_ehp297 crossref_primary_10_1016_j_jacc_2008_08_026 crossref_primary_10_1177_2045894020948780 crossref_primary_10_1016_j_cardfail_2007_11_006 crossref_primary_10_1186_s12872_020_01671_2 crossref_primary_10_3390_life13051174 crossref_primary_10_1016_j_lfs_2021_120270 crossref_primary_10_1007_s10741_015_9514_7 crossref_primary_10_1161_CIRCHEARTFAILURE_118_005537 crossref_primary_10_1161_CIRCULATIONAHA_112_000056 crossref_primary_10_1093_eurjhf_hfr147 crossref_primary_10_1186_s12916_014_0185_3 crossref_primary_10_3390_ijms24129971 crossref_primary_10_1016_j_ijcard_2016_03_035 crossref_primary_10_1016_j_jchf_2018_05_022 crossref_primary_10_1053_j_jvca_2012_07_017 crossref_primary_10_1093_ajh_hps057 crossref_primary_10_3390_jcm10235553 crossref_primary_10_1253_circj_CJ_11_1424 crossref_primary_10_1161_CIRCHEARTFAILURE_112_000096 crossref_primary_10_1183_13993003_00879_2022 crossref_primary_10_1586_ecp_09_20 crossref_primary_10_38109_2225_1685_2024_1_6_85 crossref_primary_10_1016_j_pcad_2012_07_007 crossref_primary_10_1016_S0300_8932_09_70044_2 crossref_primary_10_1093_cvr_cvw107 crossref_primary_10_14710_jai_v0i0_49535 crossref_primary_10_1093_eurjhf_hfr159 crossref_primary_10_1016_j_cardfail_2015_04_003 crossref_primary_10_1111_j_1751_7133_2011_00234_x crossref_primary_10_1517_13543776_2015_1061997 crossref_primary_10_1016_j_hfc_2023_12_010 crossref_primary_10_33549_physiolres_931951 crossref_primary_10_1097_HCO_0b013e328329e9e8 crossref_primary_10_1016_j_ehj_2013_03_004 crossref_primary_10_1016_j_ijcard_2011_05_066 crossref_primary_10_1016_j_tips_2011_02_019 crossref_primary_10_1016_S0167_5273_11_70491_0 crossref_primary_10_1007_s11936_012_0185_6 crossref_primary_10_21693_1933_088X_8_3_118 crossref_primary_10_1007_s10557_021_07306_8 crossref_primary_10_1016_S0300_8932_10_70092_0 crossref_primary_10_1111_j_1748_5827_2009_00802_x crossref_primary_10_1097_FJC_0000000000000779 crossref_primary_10_1007_s11906_013_0377_9 crossref_primary_10_1111_andr_13328 crossref_primary_10_1161_CIRCHEARTFAILURE_115_002729 crossref_primary_10_1002_ppul_21290 crossref_primary_10_1016_j_pharmthera_2008_04_003 crossref_primary_10_1258_ebm_2011_011232 crossref_primary_10_1038_aps_2016_13 crossref_primary_10_1016_j_pcad_2016_05_003 crossref_primary_10_1186_1745_6215_14_188 crossref_primary_10_1111_bph_13749 crossref_primary_10_1161_CIRCULATIONAHA_113_001458 crossref_primary_10_1016_j_lfs_2019_03_074 crossref_primary_10_1371_journal_pone_0204610 crossref_primary_10_1016_j_jacc_2013_10_033 crossref_primary_10_1182_blood_2010_09_306167 crossref_primary_10_1016_j_nucmedbio_2013_10_007 crossref_primary_10_1016_j_pcad_2016_01_005 crossref_primary_10_1097_HCO_0b013e3283522098 crossref_primary_10_1161_CIRCHEARTFAILURE_115_003011 crossref_primary_10_21693_1933_088X_14_2_70 crossref_primary_10_1161_JAHA_123_031796 crossref_primary_10_1016_j_pcad_2011_06_003 crossref_primary_10_3233_CH_189009 crossref_primary_10_1007_BF03256141 crossref_primary_10_1152_physiol_00011_2012 crossref_primary_10_1161_CIRCULATIONAHA_110_981738 crossref_primary_10_1111_chf_12008 crossref_primary_10_1016_j_healun_2016_01_020 crossref_primary_10_1177_1074248413504034 crossref_primary_10_1007_s11897_008_0018_9 crossref_primary_10_1007_s11906_015_0557_x crossref_primary_10_1016_S1155_195X_11_49831_5 crossref_primary_10_3390_jcm13020625 crossref_primary_10_1007_s11897_018_0383_y crossref_primary_10_1111_jcpt_12363 crossref_primary_10_1161_JAHA_121_022126 crossref_primary_10_1016_j_jacc_2009_01_006 crossref_primary_10_1186_s12872_017_0576_4 crossref_primary_10_1016_j_jchf_2023_05_016 crossref_primary_10_1155_2018_7056360 crossref_primary_10_3390_medicina59122190 crossref_primary_10_1161_CIRCULATIONAHA_117_031608 crossref_primary_10_3390_ijms21218263 crossref_primary_10_1136_heartjnl_2017_312865 crossref_primary_10_1007_s11897_010_0023_7 crossref_primary_10_1016_S0300_8932_10_70163_9 crossref_primary_10_1016_j_ppedcard_2012_05_011 crossref_primary_10_1093_cvr_cvab240 crossref_primary_10_1152_ajplung_00259_2017 crossref_primary_10_1161_JAHA_120_020633 crossref_primary_10_26442_00403660_2020_09_000450 crossref_primary_10_1016_j_ahj_2015_06_010 crossref_primary_10_1007_s11897_012_0106_8 crossref_primary_10_1038_hr_2015_73 crossref_primary_10_1007_s10741_008_9130_x crossref_primary_10_1016_j_jacc_2015_10_072 crossref_primary_10_1002_ejhf_47 crossref_primary_10_21693_1933_088X_14_2_79 crossref_primary_10_1007_s11897_012_0121_9 crossref_primary_10_1016_S0140_6736_11_61038_6 crossref_primary_10_1124_jpet_108_137422 crossref_primary_10_1016_S0300_8932_10_70066_X crossref_primary_10_1161_CIRCRESAHA_122_319967 crossref_primary_10_1177_2040622319887879 crossref_primary_10_1093_eurjhf_hfs152 crossref_primary_10_1111_j_1742_1241_2008_01950_x crossref_primary_10_1016_j_cardfail_2013_12_010 crossref_primary_10_1152_japplphysiol_00014_2016 crossref_primary_10_1097_FJC_0000000000000724 crossref_primary_10_1161_HYPERTENSIONAHA_117_08824 crossref_primary_10_5812_asjsm_22643 crossref_primary_10_1002_ejhf_2355 crossref_primary_10_1016_j_jjcc_2015_07_015 crossref_primary_10_1016_j_ijcard_2018_09_043 crossref_primary_10_1016_j_jvc_2012_01_001 crossref_primary_10_1538_expanim_15_0070 crossref_primary_10_1016_j_jchf_2014_02_004 crossref_primary_10_1016_j_cjca_2014_10_012 crossref_primary_10_1001_jamacardio_2019_4150 crossref_primary_10_1161_CIRCRESAHA_114_301475 crossref_primary_10_1161_CIRCHEARTFAILURE_121_008613 crossref_primary_10_1183_16000617_0059_2015 crossref_primary_10_1016_j_healun_2014_11_003 crossref_primary_10_1016_j_jacc_2008_01_024 crossref_primary_10_1016_j_repce_2012_04_020 crossref_primary_10_3109_10837450_2015_1086369 crossref_primary_10_1016_j_ijcard_2019_03_027 crossref_primary_10_3345_kjp_2016_59_6_262 crossref_primary_10_1016_j_bbr_2012_10_060 crossref_primary_10_1097_HJH_0000000000001769 crossref_primary_10_1002_ejhf_2582 crossref_primary_10_1086_678512 crossref_primary_10_1152_ajpheart_00500_2017 crossref_primary_10_1161_HYPERTENSIONAHA_119_14330 crossref_primary_10_1016_j_transproceed_2020_01_103 crossref_primary_10_1097_CPM_0000000000000264 crossref_primary_10_1016_j_healun_2015_05_016 crossref_primary_10_1016_j_phrs_2023_106931 crossref_primary_10_1097_MNH_0000000000000624 crossref_primary_10_1016_j_jacbts_2020_01_009 crossref_primary_10_57187_smw_2017_14395 crossref_primary_10_1093_eurheartj_ehac237 crossref_primary_10_2217_WHE_09_88 crossref_primary_10_1016_j_healun_2012_06_002 crossref_primary_10_1038_ijir_2009_11 crossref_primary_10_1126_scitranslmed_abl8503 crossref_primary_10_1002_phar_2314 crossref_primary_10_1016_j_ccm_2013_09_004 crossref_primary_10_1016_S1885_5857_10_70145_6 crossref_primary_10_1002_14651858_CD012621_pub2 crossref_primary_10_1111_echo_12393 crossref_primary_10_1183_13993003_02589_2017 crossref_primary_10_1053_j_jvca_2014_05_005 crossref_primary_10_1086_685021 crossref_primary_10_1111_j_1742_1241_2010_02524_x crossref_primary_10_1111_j_1742_1241_2011_02710_x crossref_primary_10_1016_j_cardfail_2010_01_003 crossref_primary_10_1007_s11883_009_0022_x crossref_primary_10_1161_CIRCRESAHA_115_302922 crossref_primary_10_1016_j_hfc_2009_11_007 crossref_primary_10_1016_j_jchf_2012_10_002 crossref_primary_10_1016_j_jacc_2019_10_048 crossref_primary_10_1161_JAHA_113_000536 crossref_primary_10_2169_internalmedicine_49_3816 crossref_primary_10_1186_1477_7525_11_161 crossref_primary_10_33678_cor_2009_068 crossref_primary_10_1021_acs_jmedchem_6b01666 crossref_primary_10_5005_ijcdas_53_2_81 crossref_primary_10_1016_j_pharmthera_2012_03_002 crossref_primary_10_1093_eurheartj_ehz364 crossref_primary_10_1097_HCO_0000000000000834 crossref_primary_10_1161_CIRCULATIONAHA_110_983866 crossref_primary_10_1038_s41569_022_00756_z crossref_primary_10_3390_jcm9113539 crossref_primary_10_1016_j_hlc_2018_04_299 crossref_primary_10_1097_PCC_0000000000000007 crossref_primary_10_1161_CIRCULATIONAHA_113_008461 crossref_primary_10_1016_j_jcmg_2017_06_013 crossref_primary_10_3390_vetsci9100530 crossref_primary_10_1007_s11897_013_0183_3 crossref_primary_10_1097_MOT_0000000000000228 crossref_primary_10_1016_S1885_5857_09_73539_X crossref_primary_10_1161_CIRCHEARTFAILURE_110_944694 crossref_primary_10_1161_CIRCHEARTFAILURE_112_969071 crossref_primary_10_1111_1440_1681_12263 crossref_primary_10_1146_annurev_pharmtox_040122_034745 crossref_primary_10_1378_chest_12_2114 crossref_primary_10_1161_CIRCULATIONAHA_111_024141 crossref_primary_10_1007_s40472_015_0075_4 crossref_primary_10_1016_j_ahj_2016_11_005 crossref_primary_10_1016_j_ijcard_2012_09_074 crossref_primary_10_1016_j_jacc_2009_04_008 crossref_primary_10_1371_journal_pone_0247987 crossref_primary_10_1016_j_ijcard_2014_12_012 crossref_primary_10_1002_ppul_21323 crossref_primary_10_1007_s10741_022_10239_5 crossref_primary_10_1007_s40256_017_0225_4 crossref_primary_10_21693_1933_088X_16_2_68 crossref_primary_10_4236_wjcd_2013_33042 crossref_primary_10_1016_j_healun_2010_02_004 crossref_primary_10_1080_19336950_2018_1547611 crossref_primary_10_1016_j_tcm_2012_07_018 crossref_primary_10_1097_MAT_0000000000000408 crossref_primary_10_1177_1753944713477518 crossref_primary_10_1016_j_healun_2009_09_003 crossref_primary_10_15829_1560_4071_2019_8_29_35 crossref_primary_10_1016_j_cardfail_2013_08_004 crossref_primary_10_1164_rccm_202302_0327SO crossref_primary_10_1016_j_healun_2012_09_009 crossref_primary_10_1016_j_pcad_2016_07_002 crossref_primary_10_1038_nrcardio_2013_12 crossref_primary_10_3389_fphys_2020_00181 crossref_primary_10_1016_j_ahj_2015_03_018 crossref_primary_10_1016_j_cardfail_2008_09_005 crossref_primary_10_1016_j_hfc_2014_07_008 crossref_primary_10_1161_CIRCHEARTFAILURE_108_785501 crossref_primary_10_1161_CIRCULATIONAHA_111_081125 crossref_primary_10_1086_674759 crossref_primary_10_1111_j_1742_1241_2008_01819_x crossref_primary_10_1586_17476348_2016_1144475 crossref_primary_10_1016_j_heliyon_2024_e27206 crossref_primary_10_1161_JAHA_124_035264 crossref_primary_10_1249_MSS_0000000000002521 crossref_primary_10_15829_1560_4071_2023_5115 crossref_primary_10_1016_j_ycar_2011_02_028 crossref_primary_10_1186_1471_2466_12_75 crossref_primary_10_1097_ACO_0b013e3283346c51 crossref_primary_10_1371_journal_pone_0119623 crossref_primary_10_1016_j_ahj_2011_05_012 crossref_primary_10_14503_THIJ_13_3671 crossref_primary_10_1007_s11897_012_0104_x crossref_primary_10_1161_CIRCHEARTFAILURE_113_000468 crossref_primary_10_1002_rcm_4568 crossref_primary_10_1111_j_1743_6109_2008_01107_x crossref_primary_10_1093_ejcts_ezs102 crossref_primary_10_1161_CIRCHEARTFAILURE_110_957050 crossref_primary_10_1161_CIRCHEARTFAILURE_108_802116 crossref_primary_10_1002_14651858_CD012621 crossref_primary_10_1086_681264 crossref_primary_10_1007_s10557_020_06959_1 crossref_primary_10_1016_j_ijcard_2014_01_102 crossref_primary_10_1016_S0300_8932_09_73130_6 crossref_primary_10_1161_CIRCRESAHA_119_313682 crossref_primary_10_1016_j_pharmthera_2017_03_011 crossref_primary_10_1016_j_pharmthera_2021_107858 crossref_primary_10_1016_S1877_1203_09_72490_5 crossref_primary_10_1161_CIRCHEARTFAILURE_112_000157 crossref_primary_10_1161_CIRCHEARTFAILURE_113_000575 crossref_primary_10_1007_s11936_008_0053_6 crossref_primary_10_1016_j_ijcard_2011_06_013 |
Cites_doi | 10.1016/S0735-1097(00)01102-5 10.2307/2530245 10.1096/fj.00-0538com 10.1016/j.amjcard.2006.08.046 10.1016/j.cardfail.2004.11.002 10.1016/j.jacc.2004.09.041 10.1056/NEJMoa042934 10.1016/0002-9149(84)90256-X 10.1161/circulationaha.106.626226 10.1016/S0002-9149(98)00344-0 10.1001/jama.297.12.1319 10.1016/S0735-1097(99)00408-8 10.1161/circ.93.6.1214 10.1161/circulationaha.106.655266 10.1016/j.brainres.2006.08.028 10.1016/0735-1097(94)00511-N 10.1164/ajrccm.163.2.2003021 10.1016/S0002-9149(98)00214-8 10.1378/chest.127.5.1647 10.1016/0735-1097(92)90050-W 10.1016/0002-8703(85)90461-2 10.1016/S0735-1097(83)80156-9 10.1056/NEJMoa050010 10.1016/S0002-9149(98)00795-4 10.1016/0735-1097(94)90859-1 10.1016/0002-9149(84)90412-0 10.1016/S0002-8703(97)70105-4 10.1016/j.ijcard.2004.12.031 10.1016/0002-8703(92)90986-6 10.1001/jama.1993.03510140062030 10.1016/j.amjcard.2006.01.033 10.1056/NEJM200006013422201 10.1159/000090555 10.1161/01.cir.0000027149.83473.b6 10.1152/ajpcell.1994.266.2.C536 10.1161/01.CIR.83.3.778 10.1016/j.jacc.2003.11.059 10.1016/S0735-1097(98)00337-4 |
ContentType | Journal Article |
Copyright | 2007 INIST-CNRS |
Copyright_xml | – notice: 2007 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TS |
DOI | 10.1161/CIRCULATIONAHA.107.716373 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Physical Education Index |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Physical Education Index |
DatabaseTitleList | MEDLINE Physical Education Index CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1524-4539 |
EndPage | 1562 |
ExternalDocumentID | 10_1161_CIRCULATIONAHA_107_716373 17785618 19141945 |
Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: HL04021 – fundername: NHLBI NIH HHS grantid: HL04022 – fundername: NHLBI NIH HHS grantid: HL070896 – fundername: NHLBI NIH HHS grantid: 5K23HL004504 – fundername: EAPO CDC HHS grantid: R21EP005294 |
GroupedDBID | --- .-D .3C .55 .GJ .XZ .Z2 01R 08R 0R~ 0ZK 18M 1CY 1J1 29B 2FS 2WC 354 40H 41~ 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAXR AAEJM AAGIX AAHPQ AAJCS AAMOA AAMTA AAPBV AAQKA AARTV AASOK AASXQ AAUGY AAWTL AAXQO AAYOK ABASU ABBUW ABDIG ABOCM ABPMR ABPTK ABQRW ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACOAL ACRKK ACRZS ACWDW ACWRI ACXNZ ADBBV ADCYY ADFPA ADGGA ADNKB AE3 AE6 AEBDS AEETU AENEX AFCHL AFDTB AFFNX AFUWQ AGINI AHMBA AHOMT AHRYX AHVBC AIJEX AJIOK AJJEV AJNWD AJNYG AKALU AKULP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW ASPBG AVWKF AWKKM AYCSE AZFZN BAWUL BOYCO BQLVK BS7 BYPQX C1A C45 CS3 DIK DIWNM DU5 DUNZO E.X E3Z EBS EEVPB EJD EX3 F2K F2L F2M F2N F5P FCALG FEDTE FL- FW0 GNXGY GQDEL GX1 H0~ H13 HZ~ H~9 IKREB IKYAY IN~ IPNFZ IQODW J5H JF9 JG8 JK3 JK8 K-A K-F K8S KD2 KMI KQ8 L-C L7B M18 MVM N4W N9A NEJ N~7 N~B N~M O9- OAG OAH OBH OCB OCUKA ODA ODMTH OGEVE OHH OHT OHYEH OJAPA OK1 OL1 OLB OLG OLH OLU OLV OLW OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ R58 RAH RHF RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W2D W3M W8F WH7 WHG WOQ WOW X3V X3W X7M XXN XYM YFH YOC YQJ YSK YXB YYM YYP YZZ ZA5 ZFV ZGI ZXP ZY1 ZZMQN ~H1 AAAAV AAIQE AAUEB ABJNI ADHPY AFEXH AHQNM AINUH AJZMW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TS |
ID | FETCH-LOGICAL-c526t-3853f1b6e4454a6ca596c5bcb3ac4baf4b8ad6b2b1ba6b75bc0055bd7c4539ca3 |
ISSN | 0009-7322 |
IngestDate | Sat Aug 17 00:02:34 EDT 2024 Fri Aug 23 02:32:54 EDT 2024 Sat Sep 28 07:53:33 EDT 2024 Sun Oct 22 16:05:45 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 14 |
Keywords | Physical exercise Human Heart failure Vasodilator agent 3',5'-Cyclic-GMP phosphodiesterase Respiratory disease Enzyme Enzyme inhibitor hypertension, pulmonary Cardiovascular disease exercise Esterases Phosphoric diester hydrolases Pulmonary hypertension Quality of life Heart disease Hydrolases Sildenafil |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c526t-3853f1b6e4454a6ca596c5bcb3ac4baf4b8ad6b2b1ba6b75bc0055bd7c4539ca3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doi.org/10.1161/circulationaha.107.716373 |
PMID | 17785618 |
PQID | 20307078 |
PQPubID | 23462 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_20307078 crossref_primary_10_1161_CIRCULATIONAHA_107_716373 pubmed_primary_17785618 pascalfrancis_primary_19141945 |
PublicationCentury | 2000 |
PublicationDate | 2007-10-02 |
PublicationDateYYYYMMDD | 2007-10-02 |
PublicationDate_xml | – month: 10 year: 2007 text: 2007-10-02 day: 02 |
PublicationDecade | 2000 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: United States |
PublicationTitle | Circulation (New York, N.Y.) |
PublicationTitleAlternate | Circulation |
PublicationYear | 2007 |
Publisher | Lippincott Williams & Wilkins |
Publisher_xml | – name: Lippincott Williams & Wilkins |
References | e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_28_2 e_1_3_2_29_2 e_1_3_2_20_2 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_1_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 e_1_3_2_14_2 e_1_3_2_35_2 |
References_xml | – ident: e_1_3_2_1_2 doi: 10.1016/S0735-1097(00)01102-5 – ident: e_1_3_2_17_2 doi: 10.2307/2530245 – ident: e_1_3_2_24_2 doi: 10.1096/fj.00-0538com – ident: e_1_3_2_20_2 doi: 10.1016/j.amjcard.2006.08.046 – ident: e_1_3_2_30_2 doi: 10.1016/j.cardfail.2004.11.002 – ident: e_1_3_2_14_2 doi: 10.1016/j.jacc.2004.09.041 – ident: e_1_3_2_35_2 doi: 10.1056/NEJMoa042934 – ident: e_1_3_2_8_2 doi: 10.1016/0002-9149(84)90256-X – ident: e_1_3_2_12_2 doi: 10.1161/circulationaha.106.626226 – ident: e_1_3_2_28_2 doi: 10.1016/S0002-9149(98)00344-0 – ident: e_1_3_2_34_2 doi: 10.1001/jama.297.12.1319 – ident: e_1_3_2_3_2 doi: 10.1016/S0735-1097(99)00408-8 – ident: e_1_3_2_31_2 doi: 10.1161/circ.93.6.1214 – ident: e_1_3_2_23_2 doi: 10.1161/circulationaha.106.655266 – ident: e_1_3_2_26_2 doi: 10.1016/j.brainres.2006.08.028 – ident: e_1_3_2_6_2 doi: 10.1016/0735-1097(94)00511-N – ident: e_1_3_2_38_2 doi: 10.1164/ajrccm.163.2.2003021 – ident: e_1_3_2_22_2 doi: 10.1016/S0002-9149(98)00214-8 – ident: e_1_3_2_25_2 doi: 10.1378/chest.127.5.1647 – ident: e_1_3_2_2_2 doi: 10.1016/0735-1097(92)90050-W – ident: e_1_3_2_4_2 doi: 10.1016/0002-8703(85)90461-2 – ident: e_1_3_2_7_2 doi: 10.1016/S0735-1097(83)80156-9 – ident: e_1_3_2_11_2 doi: 10.1056/NEJMoa050010 – ident: e_1_3_2_29_2 doi: 10.1016/S0002-9149(98)00795-4 – ident: e_1_3_2_36_2 doi: 10.1016/0735-1097(94)90859-1 – ident: e_1_3_2_16_2 doi: 10.1016/0002-9149(84)90412-0 – ident: e_1_3_2_32_2 doi: 10.1016/S0002-8703(97)70105-4 – ident: e_1_3_2_9_2 doi: 10.1016/j.ijcard.2004.12.031 – ident: e_1_3_2_15_2 doi: 10.1016/0002-8703(92)90986-6 – ident: e_1_3_2_21_2 doi: 10.1001/jama.1993.03510140062030 – ident: e_1_3_2_37_2 doi: 10.1016/j.amjcard.2006.01.033 – ident: e_1_3_2_33_2 doi: 10.1056/NEJM200006013422201 – ident: e_1_3_2_27_2 doi: 10.1159/000090555 – ident: e_1_3_2_13_2 doi: 10.1161/01.cir.0000027149.83473.b6 – ident: e_1_3_2_10_2 doi: 10.1152/ajpcell.1994.266.2.C536 – ident: e_1_3_2_18_2 doi: 10.1161/01.CIR.83.3.778 – ident: e_1_3_2_19_2 doi: 10.1016/j.jacc.2003.11.059 – ident: e_1_3_2_5_2 doi: 10.1016/S0735-1097(98)00337-4 |
SSID | ssj0006375 |
Score | 2.4935195 |
Snippet | Patients with systolic heart failure (HF) who develop secondary pulmonary hypertension (PH) have reduced exercise capacity and increased mortality compared... Background— Patients with systolic heart failure (HF) who develop secondary pulmonary hypertension (PH) have reduced exercise capacity and increased mortality... BACKGROUND: Patients with systolic heart failure (HF) who develop secondary pulmonary hypertension (PH) have reduced exercise capacity and increased mortality... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 1555 |
SubjectTerms | Aged Biological and medical sciences Blood and lymphatic vessels Blood Pressure - drug effects Cardiology. Vascular system Cardiovascular system Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Exercise Female Follow-Up Studies Heart Failure - complications Heart Failure - drug therapy Heart Failure - physiopathology Heart Rate - drug effects Humans Hypertension, Pulmonary - diagnosis Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - etiology Male Medical sciences Middle Aged Motor Activity Pharmacology. Drug treatments Phosphodiesterase 5 Inhibitors Phosphodiesterase Inhibitors - administration & dosage Phosphodiesterase Inhibitors - adverse effects Piperazines - administration & dosage Piperazines - adverse effects Pneumology Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases Pulmonary Wedge Pressure - drug effects Purines - administration & dosage Purines - adverse effects Quality of Life Sildenafil Citrate Sulfones - administration & dosage Sulfones - adverse effects Systole Treatment Outcome Vascular Resistance - drug effects Vasodilator agents. Cerebral vasodilators |
Title | Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension |
URI | https://www.ncbi.nlm.nih.gov/pubmed/17785618 https://search.proquest.com/docview/20307078 |
Volume | 116 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtMwGLbKkCYkhGDjUA7DSIibKaU5OrmMyliHtl1sq6i4iWwn1iJlSZWmSPAAPCuPwW_HOaFOHG6i1G0cpd-X_2D_B4TeOh6ocR7EBifEM-BNTIyAwMcAbNOpbQWmP5XZyGfn3nzhfFq6y9HoZy9qaVOxCf--Na_kf1CFMcBVZsn-A7LtpDAA54AvHAFhOP4VxpdpBmKDijST2Y5lISvINj2UDjmoQS5tbLk0XudOqt30LBWqUIiuqKrT22RF50IXvC6rQ0HTrNlaWEufOZbRdatNBs8mz67BfS1V8LuGtSl2kJZcNwTb1uent-5wevT55LKXJdMLPZ6Hc4U8_Zq2Y0CX44vwXKcX8d5uFvz6S_hBCazrTVnSm8FCBlEhcZ3bu60ghVrISDMZLTQQ4oFB7DqdeZJouW05huPWdZFawV5ncTYMdnpyGqwot6fzwYm1tusTT-qT2cnFbHFaVyeehxPwmCfgZtp1D5ZhDe_fdGsb8SjL6JmB495Bdy0SuHKZ4HjZBSPBZG7T808-2i56o2___tabDyyp-yu6hpda1N1YbneXlNl09RA90P4ODmvyPkKjJN9D-2FOq-LmG36HVQSy2trZQ7tnOtBjH_3oqI0bauOG2rihNgZ6Yk1tXAgsqY3THDfUxpLauKE2VtTGmtrq2pbauKU27lP7MVp8PLqazQ3dMsTgruVVhg3WpzCZlziO61CPUzfwuMs4syl3GBUO82nsMYuZjHqMwDeyCB2LCZfk4dR-gnbyIk-eIWwJcOW9QAQ0DhxmT31KOKGmLaZciDgWY2Q1f3-0qivDRMqj9sxoiBkMk6jGbIwOBkB1V2p-jNHrBrkIBL3cvaN5UmzWkaXUM_HH6GkNaHctIT64Qf7zP03-At3rXryXaKcqN8krsKkrdqDo-As6Js7E |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sildenafil+improves+exercise+capacity+and+quality+of+life+in+patients+with+systolic+heart+failure+and+secondary+pulmonary+hypertension&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=LEWIS%2C+Gregory+D&rft.au=SHAH%2C+Ravi&rft.au=SEMIGRAN%2C+Marc+J&rft.au=SHAHZAD%2C+Khurram&rft.date=2007-10-02&rft.pub=Lippincott+Williams+%26+Wilkins&rft.issn=0009-7322&rft.eissn=1524-4539&rft.volume=116&rft.issue=14&rft.spage=1555&rft.epage=1562&rft_id=info:doi/10.1161%2FCIRCULATIONAHA.107.716373&rft.externalDBID=n%2Fa&rft.externalDocID=19141945 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon |